Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10

Cancer Immunol Immunother. 1996 Sep;43(1):26-30. doi: 10.1007/s002620050299.


The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells. The original immunogen used for the development of Lym-1 was Raji Burkitt's lymphoma cell nuclei [Epstein A. L., Marder R. J., Winter J. N., Stathopoulos E., Chen F. M., Parker J. W., Taylor C. R. (1987) Cancer Res 47: 830]. The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant. We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate. Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the beta chain of HLA-DR10. This was confirmed by Edman sequencing of the isolated polypeptide chain. Western blots further show that the Lym-1 epitope is only recognized if the beta chain disulfide bonds are intact. These results imply that Lym-1 binds a discontinuous epitope on the beta chain of HLA-DR10.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm / immunology
  • Blotting, Western
  • Burkitt Lymphoma / immunology
  • Epitopes / chemistry
  • Epitopes / immunology
  • HLA-DR Antigens / genetics
  • HLA-DR Antigens / immunology*
  • Haplotypes
  • Humans
  • Lymphoma / immunology*
  • Molecular Sequence Data


  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Epitopes
  • HLA-DR Antigens